Pioglitazone in acromegaly - an open-label, prospective study.
Clin Endocrinol (Oxf)
; 77(4): 575-8, 2012 Oct.
Article
em En
| MEDLINE
| ID: mdl-22512403
ABSTRACT
OBJECTIVE:
Preclinical studies demonstrate that thiazolidinediones (TZDs) decrease growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, suggesting that they might be effective treatments for acromegaly. This study investigated the effect of pioglitazone on biochemical indices of disease activity in acromegaly. DESIGN ANDPARTICIPANTS:
This was a 4-month open-label prospective study in 16 patients with active acromegaly who were attending public hospital endocrinology clinics.METHODS:
The intervention was pioglitazone 45 mg/day. The primary outcome was change in serum IGF-1; the secondary outcome was change in area under the curve of glucose-suppressed GH.RESULTS:
Serum IGF-1 did not change during treatment with pioglitazone (P = 0·95). After 4 months, the mean (95% CI) change from baseline was -1 µg/l (-51, 49). GH levels following oral glucose loading were unchanged during pioglitazone therapy. After 4 months, the mean (95% CI) change from baseline in area under curve for glucose-suppressed GH was 31 µg/l (-75, 138, P = 0·54).CONCLUSIONS:
Short-term treatment with conventional doses of pioglitazone did not improve biochemical measures of disease activity in acromegaly.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Acromegalia
/
Tiazolidinedionas
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article